Hypoxia-inducible factor-1α is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy
出版年份 2019 全文链接
标题
Hypoxia-inducible factor-1α is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy
作者
关键词
-
出版物
Scientific Reports
Volume 9, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-10-14
DOI
10.1038/s41598-019-51343-1
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Hypoxia Signaling in the Skeleton: Implications for Bone Health
- (2019) Clare E. Yellowley et al. Current Osteoporosis Reports
- Analysis from the EMPA-REG OUTCOME® trial indicate empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics
- (2019) Gert J. Mayer et al. KIDNEY INTERNATIONAL
- Effect of SGLT2 inhibitors on body composition, fluid status and renin–angiotensin–aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy
- (2019) Anja Schork et al. Cardiovascular Diabetology
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nephropathy in diabetic db/db mice is accelerated by high protein diet and improved by the SGLT2 inhibitor dapagliflozin
- (2019) Sisse Andersen Nørgaard et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Dapagliflozin Aggravates Renal Injury via Promoting Gluconeogenesis in db/db Mice
- (2018) Yingli Jia et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Renal scattered tubular-like cells confer protective effects in the stenotic murine kidney mediated by release of extracellular vesicles
- (2018) Xiangyu Zou et al. Scientific Reports
- A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor–dependent pathway after renal injury in mice
- (2018) Yifan Zhang et al. KIDNEY INTERNATIONAL
- Empagliflozin, SGLT2 inhibitor, attenuates renal fibrosis in rats exposed to unilateral ureteric obstruction: potential role of klotho expression
- (2018) Noha A. T. Abbas et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETOLOGIA
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impacts of Diabetes and an SGLT2 Inhibitor on the Glomerular Number and Volume in db/db Mice, as Estimated by Synchrotron Radiation Micro-CT at SPring-8
- (2018) Yumi Takiyama et al. EBioMedicine
- SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy
- (2017) Xiaoxin X. Wang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Fructose-1,6-bisphosphate and aldolase mediate glucose sensing by AMPK
- (2017) Chen-Song Zhang et al. NATURE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- HIF-1 Mediates Renal Fibrosis in OVE26 Type 1 Diabetic Mice
- (2016) Bijaya K. Nayak et al. DIABETES
- The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels
- (2016) Simon A. Hawley et al. DIABETES
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration
- (2016) Linda A. Villani et al. Molecular Metabolism
- Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice
- (2016) Linda A. Gallo et al. Scientific Reports
- Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice
- (2014) Bowen Lin et al. Cardiovascular Diabetology
- Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes
- (2014) David Z.I. Cherney et al. KIDNEY INTERNATIONAL
- Phenotypic characteristics of diabetic kidney involvement
- (2014) Roland C. Blantz KIDNEY INTERNATIONAL
- Long-Term Treatment with the Sodium Glucose Cotransporter 2 Inhibitor, Dapagliflozin, Ameliorates Glucose Homeostasis and Diabetic Nephropathy in db/db Mice
- (2014) Naoto Terami et al. PLoS One
- Inhibition of Kidney Proximal Tubular Glucose Reabsorption Does Not Prevent against Diabetic Nephropathy in Type 1 Diabetic eNOS Knockout Mice
- (2014) Muralikrishna Gangadharan Komala et al. PLoS One
- Stable Expression of Hypoxia-Inducible Factor-1α in Human Renal Proximal Tubular Epithelial Cells Promotes Epithelial to Mesenchymal Transition
- (2014) L. Luo et al. TRANSPLANTATION PROCEEDINGS
- Hypoxia in Diabetic Kidneys
- (2014) Yumi Takiyama et al. Biomed Research International
- Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function indb/dbmice
- (2013) T Nagata et al. BRITISH JOURNAL OF PHARMACOLOGY
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
- (2013) David Z.I. Cherney et al. CIRCULATION
- AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo
- (2012) Brandon Faubert et al. Cell Metabolism
- Pyruvate Kinase M2 Is a PHD3-Stimulated Coactivator for Hypoxia-Inducible Factor 1
- (2011) Weibo Luo et al. CELL
- Tubular Injury in a Rat Model of Type 2 Diabetes Is Prevented by Metformin
- (2011) Yumi Takiyama et al. DIABETES
- The Role of the Mammalian Target Of Rapamycin (mTOR) in Renal Disease
- (2009) W. Lieberthal et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Hypoxia-inducible factor-1α induces Twist expression in tubular epithelial cells subjected to hypoxia, leading to epithelial-to-mesenchymal transition
- (2009) Shiren Sun et al. KIDNEY INTERNATIONAL
- Upregulated IL-18 expression in type 2 diabetic subjects with nephropathy: TGF-β1 enhanced IL-18 expression in human renal proximal tubular epithelial cells
- (2008) Kazunari Miyauchi et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Hypoxia and Hypoxia-Inducible Factor in Renal Disease
- (2008) Masaomi Nangaku et al. NEPHRON EXPERIMENTAL NEPHROLOGY
- Mechanisms of Disease: the hypoxic tubular hypothesis of diabetic nephropathy
- (2008) Dhruv K Singh et al. Nature clinical practice. Nephrology
- Adaptation to hypoxia in the diabetic rat kidney
- (2007) C. Rosenberger et al. KIDNEY INTERNATIONAL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation